Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Zohren F"" wg kryterium: Autor


Tytuł :
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
Autorzy :
Sternberg CN; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Fizazi K; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Saad F; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Shore ND; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
De Giorgi U; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Penson DF; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Ferreira U; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Efstathiou E; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Madziarska K; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Kolinsky MP; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Cubero DIG; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Noerby B; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Zohren F; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Lin X; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Modelska K; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Sugg J; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Steinberg J; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Hussain M; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Pokaż więcej
Corporate Authors :
PROSPER Investigators
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Jun 04; Vol. 382 (23), pp. 2197-2206. Date of Electronic Publication: 2020 May 29.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*drug therapy
Androgen Antagonists/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Phenylthiohydantoin/*analogs & derivatives
Prostatic Neoplasms, Castration-Resistant/*drug therapy
Adenocarcinoma/mortality ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Double-Blind Method ; Humans ; Kallikreins/blood ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Phenylthiohydantoin/adverse effects ; Phenylthiohydantoin/therapeutic use ; Placebos ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms, Castration-Resistant/mortality ; Survival Analysis
Czasopismo naukowe
Tytuł :
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.
Autorzy :
Moore KN; Stephenson Oklahoma Cancer Center, University of Oklahoma, Norman, Oklahoma, USA.
Bauer TM; Sarah Cannon Research Institute/Tennessee Oncology, PPLC, Nashville, Tennessee, USA.
Falchook GS; Denver Drug Development Unit, Sarah Cannon Research Institute at HealthONE, Denver, Colorado, USA.
Chowdhury S; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.
Patel C; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.
Neuwirth R; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.
Enke A; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.
Zohren F; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.
Patel MR; Drug Development Unit, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida, USA.
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2018 Feb 01; Vol. 3 (2), pp. e000291. Date of Electronic Publication: 2018 Feb 01 (Print Publication: 2018).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies.
Autorzy :
Juric D; Massachusetts General Hospital, Boston, Massachusetts. .
de Bono JS; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
LoRusso PM; Yale University, New Haven, Connecticut.
Nemunaitis J; Mary Crowley Cancer Research Center, Dallas, Texas.
Heath EI; Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
Kwak EL; Massachusetts General Hospital, Boston, Massachusetts.
Macarulla Mercadé T; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
Geuna E; Investigative Clinical Oncology, Fondazione Del Piemonte Per L'Oncologia, Candiolo Cancer Institute, Candiolo, Italy.
Jose de Miguel-Luken M; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
Patel C; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Kuida K; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Sankoh S; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Westin EH; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Zohren F; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Shou Y; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Tabernero J; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Sep 01; Vol. 23 (17), pp. 5015-5023. Date of Electronic Publication: 2017 May 10.
Typ publikacji :
Clinical Trial, Phase I; Journal Article
MeSH Terms :
Benzoxazoles/*administration & dosage
Class I Phosphatidylinositol 3-Kinases/*genetics
Imidazoles/*administration & dosage
Morpholines/*administration & dosage
Neoplasms/*drug therapy
Protein Kinase Inhibitors/*administration & dosage
Pyridines/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Benzoxazoles/adverse effects ; Dose-Response Relationship, Drug ; Female ; Humans ; Imidazoles/adverse effects ; Male ; Middle Aged ; Morpholines/adverse effects ; Neoplasm Staging ; Neoplasms/genetics ; Neoplasms/pathology ; Protein Kinase Inhibitors/adverse effects ; Pyridines/adverse effects
Czasopismo naukowe
Tytuł :
TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.
Autorzy :
Burris HA 3rd; Sarah Cannon Research Institute, 250 25th Avenue North, #100, Nashville, TN, 37203, USA. .; Tennessee Oncology PLLC, Nashville, TN, USA. .
Kurkjian CD; Sarah Cannon Research Institute, 250 25th Avenue North, #100, Nashville, TN, 37203, USA.; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Hart L; Sarah Cannon Research Institute, 250 25th Avenue North, #100, Nashville, TN, 37203, USA.; Florida Cancer Specialists, Fort Myers, FL, USA.
Pant S; Sarah Cannon Research Institute, 250 25th Avenue North, #100, Nashville, TN, 37203, USA.; Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Murphy PB; Sarah Cannon Research Institute, 250 25th Avenue North, #100, Nashville, TN, 37203, USA.; Tennessee Oncology PLLC, Nashville, TN, USA.
Jones SF; Sarah Cannon Research Institute, 250 25th Avenue North, #100, Nashville, TN, 37203, USA.
Neuwirth R; Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Patel CG; Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Zohren F; Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Infante JR; Sarah Cannon Research Institute, 250 25th Avenue North, #100, Nashville, TN, 37203, USA.; Tennessee Oncology PLLC, Nashville, TN, USA.
Pokaż więcej
Źródło :
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2017 Aug; Vol. 80 (2), pp. 261-273. Date of Electronic Publication: 2017 Jun 10.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Benzoxazoles/*administration & dosage
Neoplasms/*drug therapy
Pyrimidines/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Benzoxazoles/adverse effects ; Benzoxazoles/pharmacokinetics ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Maximum Tolerated Dose ; Mechanistic Target of Rapamycin Complex 1 ; Mechanistic Target of Rapamycin Complex 2 ; Middle Aged ; Multiprotein Complexes/antagonists & inhibitors ; Neoplasms/pathology ; Paclitaxel/administration & dosage ; Pyrimidines/adverse effects ; Pyrimidines/pharmacokinetics ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; Trastuzumab/administration & dosage ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
Autorzy :
Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Siegel DS; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey.
Vij R; Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, Missouri.
Berdeja JG; Sarah Cannon Research Institute, Nashville, Tennessee.
Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Neuwirth R; Global Biostatistics, Millennium Pharmaceuticals, Inc, Cambridge, Massachusetts, USA, a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited.
Patel CG; Clinical Pharmacology, Millennium Pharmaceuticals, Inc, Cambridge, Massachusetts, USA, a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited.
Zohren F; Oncology Clinical Research, Millennium Pharmaceuticals, Inc, Cambridge, Massachusetts, USA, a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited.
Wolf JL; Department of Medicine, University of California San Francisco, San Francisco, California.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2016 Jun; Vol. 91 (4), pp. 400-5.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Benzoxazoles/*therapeutic use
Lymphoma, Non-Hodgkin/*drug therapy
Multiple Myeloma/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Pyrimidines/*therapeutic use
Waldenstrom Macroglobulinemia/*drug therapy
Administration, Oral ; Aged ; Aged, 80 and over ; Antineoplastic Agents/pharmacology ; Benzoxazoles/pharmacology ; Drug Monitoring ; Female ; Humans ; Lymphoma, Non-Hodgkin/diagnosis ; Male ; Maximum Tolerated Dose ; Mechanistic Target of Rapamycin Complex 1 ; Mechanistic Target of Rapamycin Complex 2 ; Middle Aged ; Multiple Myeloma/diagnosis ; Multiprotein Complexes/antagonists & inhibitors ; Neoplasm Grading ; Neoplasm Staging ; Protein Kinase Inhibitors/pharmacology ; Pyrimidines/pharmacology ; Recurrence ; Retreatment ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; Treatment Outcome ; Waldenstrom Macroglobulinemia/diagnosis
Czasopismo naukowe
Tytuł :
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.
Autorzy :
Zohren F; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Bruns I; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Pechtel S; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Schroeder T; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Fenk R; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Czibere A; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Maschmeyer G; Klinikum Ernst von Bergmann, Potsdam, Germany;
Kofahl-Krause D; Medizinische Hochschule Hannover, Hannover, Germany;
Niederle N; Klinikum Leverkusen, Leverkusen, Germany;
Heil G; Kreiskrankenhaus Lüdenscheid, Lüdenscheid, Germany;
Losem C; Onkologische Praxis Neuss, Neuss, Germany;
Welslau M; Onkologische Praxis Aschaffenburg, Aschaffenburg, Germany;
Brugger W; Schwarzwald-Baar-Klinikum Villingen, Villingen, Germany; and.
Germing U; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Kronenwett R; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Barth J; Justus-Liebig-Universität, Giessen, Germany.
Rummel MJ; Justus-Liebig-Universität, Giessen, Germany.
Haas R; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Kobbe G; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Pokaż więcej
Źródło :
Blood [Blood] 2015 Sep 17; Vol. 126 (12), pp. 1407-14. Date of Electronic Publication: 2015 Aug 03.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphoma, Follicular/*blood
Lymphoma, Follicular/*drug therapy
Oncogene Proteins, Fusion/*blood
Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Bendamustine Hydrochloride/administration & dosage ; Bendamustine Hydrochloride/therapeutic use ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/therapeutic use ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Doxorubicin/therapeutic use ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Lymphoma, Follicular/diagnosis ; Lymphoma, Follicular/genetics ; Male ; Middle Aged ; Prednisone/administration & dosage ; Prednisone/therapeutic use ; Prognosis ; Rituximab/administration & dosage ; Rituximab/therapeutic use ; Vincristine/administration & dosage ; Vincristine/therapeutic use
Czasopismo naukowe
Tytuł :
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.
Autorzy :
Schroeder T; Medical Faculty, Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, Germany. />Czibere A
Platzbecker U
Bug G
Uharek L
Luft T
Giagounidis A
Zohren F
Bruns I
Wolschke C
Rieger K
Fenk R
Germing U
Haas R
Kröger N
Kobbe G
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2013 Jun; Vol. 27 (6), pp. 1229-35. Date of Electronic Publication: 2013 Jan 14.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Cell Transplantation*
Salvage Therapy*
Stem Cell Transplantation*
Antimetabolites, Antineoplastic/*therapeutic use
Azacitidine/*therapeutic use
Leukemia, Myeloid, Acute/*therapy
Lymphocytes/*cytology
Myelodysplastic Syndromes/*therapy
Adult ; Aged ; Combined Modality Therapy ; Female ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/surgery ; Male ; Middle Aged ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/surgery ; Recurrence ; Transplantation, Homologous
Czasopismo naukowe
Tytuł :
Ataxin1L is a regulator of HSC function highlighting the utility of cross-tissue comparisons for gene discovery.
Autorzy :
Kahle JJ; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, United States of America.
Souroullas GP
Yu P
Zohren F
Lee Y
Shaw CA
Zoghbi HY
Goodell MA
Pokaż więcej
Źródło :
PLoS genetics [PLoS Genet] 2013 Mar; Vol. 9 (3), pp. e1003359. Date of Electronic Publication: 2013 Mar 28.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Ataxia*/genetics
Ataxia*/metabolism
Autistic Disorder*/genetics
Autistic Disorder*/metabolism
Gene Regulatory Networks*
Hematopoietic Stem Cells*/cytology
Hematopoietic Stem Cells*/metabolism
Nerve Tissue Proteins*/genetics
Nerve Tissue Proteins*/metabolism
Nuclear Proteins*/genetics
Nuclear Proteins*/metabolism
Animals ; Ataxin-1 ; Ataxins ; Brain/metabolism ; Cell Differentiation ; Cell Proliferation ; Gene Expression Regulation ; Genetic Association Studies ; Mice ; Organ Specificity ; Protein Interaction Maps
Czasopismo naukowe
Tytuł :
Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells.
Autorzy :
Bruns I; Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany. />Cadeddu RP
Brueckmann I
Fröbel J
Geyh S
Büst S
Fischer JC
Roels F
Wilk CM
Schildberg FA
Hünerlitürkoglu AN
Zilkens C
Jäger M
Steidl U
Zohren F
Fenk R
Kobbe G
Brors B
Czibere A
Schroeder T
Trumpp A
Haas R
Pokaż więcej
Źródło :
Blood [Blood] 2012 Sep 27; Vol. 120 (13), pp. 2620-30. Date of Electronic Publication: 2012 Apr 18.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antigens, CD34/*metabolism
Biomarkers/*metabolism
Bone Marrow/*pathology
Hematopoietic Stem Cells/*pathology
Megakaryocyte-Erythroid Progenitor Cells/*pathology
Multiple Myeloma/*metabolism
Multiple Myeloma/*pathology
Animals ; Blotting, Western ; Bone Marrow/metabolism ; Case-Control Studies ; Cell Adhesion ; Cell Cycle ; Cell Differentiation ; Cell Movement ; Cell Proliferation ; Cells, Cultured ; Female ; Flow Cytometry ; Fluorescent Antibody Technique ; Gene Expression Profiling ; Hematopoietic Stem Cells/metabolism ; Humans ; Immunoenzyme Techniques ; Male ; Megakaryocyte-Erythroid Progenitor Cells/metabolism ; Mesenchymal Stem Cells/metabolism ; Mesenchymal Stem Cells/pathology ; Mice ; Mice, Inbred NOD ; Multiple Myeloma/genetics ; Oligonucleotide Array Sequence Analysis ; RNA, Messenger/genetics ; Real-Time Polymerase Chain Reaction ; Reverse Transcriptase Polymerase Chain Reaction ; Signal Transduction
Czasopismo naukowe
Tytuł :
The transcription factor Lyl-1 regulates lymphoid specification and the maintenance of early T lineage progenitors.
Autorzy :
Zohren F; Department of Haematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany.
Souroullas GP
Luo M
Gerdemann U
Imperato MR
Wilson NK
Göttgens B
Lukov GL
Goodell MA
Pokaż więcej
Źródło :
Nature immunology [Nat Immunol] 2012 Jul 08; Vol. 13 (8), pp. 761-9. Date of Electronic Publication: 2012 Jul 08.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Lymphopoiesis*
Basic Helix-Loop-Helix Transcription Factors/*metabolism
Lymphoid Progenitor Cells/*physiology
Neoplasm Proteins/*metabolism
T-Lymphocytes/*immunology
Animals ; Apoptosis/immunology ; Basic Helix-Loop-Helix Transcription Factors/deficiency ; Basic Helix-Loop-Helix Transcription Factors/genetics ; Bone Marrow Cells/physiology ; CD4 Antigens/biosynthesis ; CD8 Antigens/biosynthesis ; Cell Lineage ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/metabolism ; Lymphoid Progenitor Cells/cytology ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Neoplasm Proteins/deficiency ; Neoplasm Proteins/genetics ; T-Lymphocytes/physiology ; Thymocytes/physiology ; Transcription Factors/genetics ; Transcription Factors/metabolism
Czasopismo naukowe
Tytuł :
The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter.
Autorzy :
Korthals M; Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany.
Sehnke N
Kronenwett R
Bruns I
Mau J
Zohren F
Haas R
Kobbe G
Fenk R
Pokaż więcej
Źródło :
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation [Biol Blood Marrow Transplant] 2012 Mar; Vol. 18 (3), pp. 423-431.e3. Date of Electronic Publication: 2011 Jul 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Peripheral Blood Stem Cell Transplantation*
Bone Marrow/*pathology
Multiple Myeloma/*pathology
Multiple Myeloma/*therapy
Adult ; Aged ; Combined Modality Therapy ; Female ; Humans ; Immunoglobulin Heavy Chains/genetics ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Multiple Myeloma/immunology ; Multiple Myeloma/surgery ; Neoplasm, Residual ; Prognosis ; Real-Time Polymerase Chain Reaction/methods ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Autorzy :
Saure C; Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Duesseldorf, Germany.
Schroeder T
Zohren F
Groten A
Bruns I
Czibere A
Galonska L
Kondakci M
Weigelt C
Fenk R
Germing U
Haas R
Kobbe G
Pokaż więcej
Źródło :
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation [Biol Blood Marrow Transplant] 2012 Mar; Vol. 18 (3), pp. 466-72. Date of Electronic Publication: 2011 Sep 29.
Typ publikacji :
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Hematopoietic Stem Cell Transplantation/*methods
Leukemia, Myeloid, Acute/*therapy
Myelodysplastic Syndromes/*therapy
Transplantation Conditioning/*methods
Adult ; Aged ; Amsacrine/administration & dosage ; Busulfan/administration & dosage ; Cyclophosphamide/administration & dosage ; Cytarabine/administration & dosage ; Disease-Free Survival ; Female ; Graft vs Host Disease/etiology ; Graft vs Host Disease/prevention & control ; Hematopoietic Stem Cell Transplantation/adverse effects ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/surgery ; Male ; Melphalan/administration & dosage ; Middle Aged ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/surgery ; Transplantation Conditioning/adverse effects ; Transplantation, Homologous ; Unrelated Donors ; Vidarabine/administration & dosage ; Vidarabine/analogs & derivatives
Czasopismo naukowe
Tytuł :
Therapy-related myeloid neoplasms following treatment with radioiodine.
Autorzy :
Schroeder T; Department for Haematology, Oncology and Clinical Immunology, University of Duesseldorf Medical Faculty, Duesseldorf, Germany. />Kuendgen A
Kayser S
Kröger N
Braulke F
Platzbecker U
Klärner V
Zohren F
Haase D
Stadler M
Schlenk R
Czibere AG
Bruns I
Fenk R
Gattermann N
Haas R
Kobbe G
Germing U
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2012 Feb; Vol. 97 (2), pp. 206-12. Date of Electronic Publication: 2011 Oct 11.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Leukemia, Myeloid, Acute/*epidemiology
Myelodysplastic Syndromes/*epidemiology
Neoplasms, Radiation-Induced/*epidemiology
Neoplasms, Second Primary/*epidemiology
Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Iodine Radioisotopes/adverse effects ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Myelodysplastic Syndromes/mortality ; Neoplasms, Radiation-Induced/mortality ; Neoplasms, Second Primary/mortality ; Retrospective Studies ; Survival Rate ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors.
Autorzy :
Saure C; Department of Hematology, Oncology, and Clinical Immunology, University of Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany. />Warnke C
Zohren F
Schroeder T
Bruns I
Cadeddu RP
Weigelt C
Fischer U
Kobbe G
Hartung HP
Adams O
Kieseier BC
Haas R
Pokaż więcej
Źródło :
Archives of neurology [Arch Neurol] 2011 Nov; Vol. 68 (11), pp. 1428-31.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Antigens, CD34/*biosynthesis
Hematopoietic Stem Cells/*metabolism
Multiple Sclerosis, Relapsing-Remitting/*blood
Receptors, Lymphocyte Homing/*biosynthesis
Antibodies, Monoclonal, Humanized/pharmacology ; Antigens, CD34/blood ; Cell Migration Inhibition/drug effects ; Cell Migration Inhibition/physiology ; Cell Movement/drug effects ; Cell Movement/physiology ; Cells, Cultured ; Hematopoietic Stem Cells/drug effects ; Humans ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Natalizumab ; Receptors, Lymphocyte Homing/blood
Czasopismo naukowe
Tytuł :
Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases.
Autorzy :
Zohren F; Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine-University, Düsseldorf, Germany. zohren@bcm.tmc.edu
Schroeder T
Czibere A
Fenk R
Bruns I
Kondakci M
Saure C
Haas R
Kobbe G
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2011 May; Vol. 46 (5), pp. 747-55. Date of Electronic Publication: 2010 Jul 26.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Graft vs Host Disease/*prevention & control
Immunosuppressive Agents/*therapeutic use
Mycophenolic Acid/*analogs & derivatives
Tacrolimus/*administration & dosage
Adult ; Aged ; Female ; Hematologic Diseases/drug therapy ; Humans ; Male ; Middle Aged ; Mycophenolic Acid/administration & dosage ; Mycophenolic Acid/therapeutic use ; Tacrolimus/therapeutic use ; Transplantation Chimera ; Transplantation Conditioning/adverse effects ; Transplantation Conditioning/methods ; Transplantation, Homologous ; Treatment Outcome ; Vidarabine/analogs & derivatives ; Vidarabine/therapeutic use ; Whole-Body Irradiation
Czasopismo naukowe
Tytuł :
The Mexican way: a feasible approach to avoid DMSO toxicity.
Autorzy :
Schroeder T
Fenk R
Saure C
Czibere A
Bruns I
Zohren F
Haas R
Kobbe G
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2011 Mar; Vol. 46 (3), pp. 469-71. Date of Electronic Publication: 2010 Jun 14.
Typ publikacji :
Case Reports; Comment; Letter
MeSH Terms :
Dimethyl Sulfoxide*
Hematopoietic Stem Cells*
Blood Preservation/*methods
Peripheral Blood Stem Cell Transplantation/*methods
Aged ; Humans ; Male ; Mexico ; Middle Aged
Raport
Tytuł :
5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis.
Autorzy :
Czibere A; Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany. />Bruns I
Kröger N
Platzbecker U
Lind J
Zohren F
Fenk R
Germing U
Schröder T
Gräf T
Haas R
Kobbe G
Pokaż więcej
Źródło :
Bone marrow transplantation [Bone Marrow Transplant] 2010 May; Vol. 45 (5), pp. 872-6. Date of Electronic Publication: 2009 Oct 12.
Typ publikacji :
Journal Article
MeSH Terms :
Azacitidine/*therapeutic use
Leukemia, Myeloid, Acute/*therapy
Myelodysplastic Syndromes/*therapy
Stem Cell Transplantation/*adverse effects
Adult ; Aged ; Female ; Graft vs Host Disease/complications ; Graft vs Host Disease/drug therapy ; Humans ; Male ; Middle Aged ; Recurrence ; Retrospective Studies ; Risk Factors ; Salvage Therapy ; Survival Analysis ; Transplantation, Homologous
Czasopismo naukowe
Tytuł :
Bendamustine in patients with relapsed or refractory multiple myeloma.
Autorzy :
Michael M; Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany.
Bruns I
Bölke E
Zohren F
Czibere A
Safaian NN
Neumann F
Haas R
Kobbe G
Fenk R
Pokaż więcej
Źródło :
European journal of medical research [Eur J Med Res] 2010 Jan 29; Vol. 15 (1), pp. 13-9.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Multiple Myeloma/*drug therapy
Nitrogen Mustard Compounds/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Bendamustine Hydrochloride ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Nitrogen Mustard Compounds/adverse effects ; Recurrence ; Retrospective Studies ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy.
Autorzy :
Schroeder T; University of Duesseldorf, Medical Faculty, Department of Haematology, Oncology and Clinical Immunology, Duesseldorf, Germany. />Zohren F
Saure C
Bruns I
Czibere A
Safaian NN
Fenk R
Haas R
Kobbe G
Pokaż więcej
Źródło :
Acta haematologica [Acta Haematol] 2010; Vol. 124 (3), pp. 153-9. Date of Electronic Publication: 2010 Oct 11.
Typ publikacji :
Journal Article
MeSH Terms :
Mutation*
Antineoplastic Agents/*therapeutic use
Benzenesulfonates/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Leukemia, Myeloid, Acute/*genetics
Pyridines/*therapeutic use
fms-Like Tyrosine Kinase 3/*genetics
Adult ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Benzenesulfonates/administration & dosage ; Benzenesulfonates/adverse effects ; Enzyme Activation/genetics ; Female ; Humans ; Leukemia, Myeloid, Acute/enzymology ; Male ; Middle Aged ; Niacinamide/analogs & derivatives ; Phenylurea Compounds ; Pyridines/administration & dosage ; Pyridines/adverse effects ; Retrospective Studies ; Sorafenib ; Treatment Outcome ; Young Adult ; fms-Like Tyrosine Kinase 3/metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies